search
Back to results

Study of HTD4010 in Healthy Volunteers

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
HTD4010
Sponsored by
HighTide Biopharma Pty Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

For volunteers in SAD:

Inclusion Criteria:

  1. Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2
  2. Non-diabetic, fasting plasma glucose < 5.6 mmol/L
  3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for ≥12 months.

    Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the participant and his partner must be using an acceptable, highly effective, contraceptive method from screening and for a period of 60 days after the last dose of Study Drug.

  4. Ability to provide written informed consent.

Exclusion Criteria:

  1. Systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg at screening.
  2. Pregnant or lactating women
  3. Participation in an investigational study within 30 days prior to dosing or 5 half-lives within the last dose of investigational product whichever is longer.
  4. Current use of any prescription or over-the-counter (OTC) medications, including herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives, whichever is longer. Use of ≤2g paracetamol per day is allowed prior to and during the study at Investigator discretion.
  5. Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.
  6. History of any major surgery within 6 months prior to Screening
  7. History of any serious adverse reaction or hypersensitivity to any of the product components.
  8. Use of parenterally administered proteins or antibodies within 12 weeks of screening.

etc.

Sites / Locations

  • Linear Clinical Research Limited

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

50mg in SAD

100mg in SAD

200mg in SAD

300mg in SAD

Arm Description

single dose of 50mg HTD4010 or placebo injectable in healthy volunteers

single dose of 100mg HTD4010 or placebo injectable in healthy volunteers

single dose of 200mg HTD4010 or placebo injectable in healthy volunteers

single dose of 300mg HTD4010 or placebo injectable in healthy volunteers

Outcomes

Primary Outcome Measures

Incidence, severity and causality of adverse events

Secondary Outcome Measures

Full Information

First Posted
August 31, 2015
Last Updated
July 23, 2020
Sponsor
HighTide Biopharma Pty Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02538848
Brief Title
Study of HTD4010 in Healthy Volunteers
Official Title
A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
October 2015 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HighTide Biopharma Pty Ltd

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To investigate safety and tolerability of HTD4010 after single ascending doses (SAD) in healthy volunteers
Detailed Description
Safety, tolerability and pharmacokinetics(PK) assessments are the outcome measure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
50mg in SAD
Arm Type
Experimental
Arm Description
single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
Arm Title
100mg in SAD
Arm Type
Experimental
Arm Description
single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
Arm Title
200mg in SAD
Arm Type
Experimental
Arm Description
single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
Arm Title
300mg in SAD
Arm Type
Experimental
Arm Description
single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
Intervention Type
Drug
Intervention Name(s)
HTD4010
Other Intervention Name(s)
analog of INGAP peptide
Intervention Description
injectable solution
Primary Outcome Measure Information:
Title
Incidence, severity and causality of adverse events
Time Frame
One day in SAD

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
For volunteers in SAD: Inclusion Criteria: Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2 Non-diabetic, fasting plasma glucose < 5.6 mmol/L Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for ≥12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the participant and his partner must be using an acceptable, highly effective, contraceptive method from screening and for a period of 60 days after the last dose of Study Drug. Ability to provide written informed consent. Exclusion Criteria: Systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg at screening. Pregnant or lactating women Participation in an investigational study within 30 days prior to dosing or 5 half-lives within the last dose of investigational product whichever is longer. Current use of any prescription or over-the-counter (OTC) medications, including herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives, whichever is longer. Use of ≤2g paracetamol per day is allowed prior to and during the study at Investigator discretion. Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing. History of any major surgery within 6 months prior to Screening History of any serious adverse reaction or hypersensitivity to any of the product components. Use of parenterally administered proteins or antibodies within 12 weeks of screening. etc.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janakan Krishnarajah, Doctor
Organizational Affiliation
Linear Clinical Research Limited
Official's Role
Principal Investigator
Facility Information:
Facility Name
Linear Clinical Research Limited
City
Perth
ZIP/Postal Code
WA6009
Country
Australia

12. IPD Sharing Statement

Learn more about this trial

Study of HTD4010 in Healthy Volunteers

We'll reach out to this number within 24 hrs